AI-text
Zyprexa (olanzapine) has faced significant criticism regarding its marketing practices, safety profile, and off-label usage. In 2009, manufacturer Eli Lilly pleaded guilty to illegally marketing the drug for unapproved uses and agreed to pay a $1.4 billion fine, one of the largest corporate settlements in history. Internal documents revealed the company downplayed serious health risks to protect sales, despite knowing the drug caused significant weight gain and elevated blood sugar.
The medication carries a Boxed Warning for an increased risk of death in elderly patients with dementia-related psychosis, leading to its prohibition for this condition. Critics argue it is frequently prescribed off-label for conditions like insomnia, anxiety, and ADHD in children and the elderly, despite a lack of strong evidence supporting its efficacy for these uses.
Common adverse effects drive much of the patient criticism, including rapid weight gain, hyperglycemia, and diabetes. Users frequently report severe side effects such as tardive dyskinesia, sedation, emotional numbness, and difficult withdrawal symptoms (discontinuation syndrome), with some claiming the drug permanently alters personality and brain chemistry. Additionally, studies have linked atypical antipsychotics like Zyprexa to a higher risk of cardiovascular events, including heart attacks and strokes.
km
npub1ft…43gst
2026-10-05 13:57:32 UTC
in reply to nevent1q…46m6
Author Public Key
npub1ft5fucemz407r284323h56rsftws05wn3pqnudvda2ddp2mfhrust43gstSeen on
wss://relay.momostr.pinkPublished at
2026-10-05 13:57:32 UTCEvent JSON
{
"id": "117a0f96bfce3997ac93c6309c84aa5c397606137019c15feaf737c189f88e17",
"pubkey": "4ae89e633b155fe1a8f58aa37a68704add07d1d388413e358dea9ad0ab69b8f9",
"created_at": 1791208652,
"kind": 1,
"tags": [
[
"p",
"4ae89e633b155fe1a8f58aa37a68704add07d1d388413e358dea9ad0ab69b8f9"
],
[
"e",
"e33b18d0c0a6f971d8d40d953973aa9f1aed4219417f15f5e0594f7aaacc1ee1",
"",
"root",
"4ae89e633b155fe1a8f58aa37a68704add07d1d388413e358dea9ad0ab69b8f9"
],
[
"e",
"260e88a962c624013357109eaa0da7abf9b18f6728514bcd6f6eee2779bc9047",
"",
"reply",
"4ae89e633b155fe1a8f58aa37a68704add07d1d388413e358dea9ad0ab69b8f9"
],
[
"proxy",
"https://km.produkti.se/objects/3cc40c13-6651-4640-87d5-455d0487f847",
"activitypub"
],
[
"L",
"pink.momostr"
],
[
"l",
"pink.momostr.activitypub:https://km.produkti.se/objects/3cc40c13-6651-4640-87d5-455d0487f847",
"pink.momostr"
],
[
"-"
]
],
"content": "AI-text\r\n\r\nZyprexa (olanzapine) has faced significant criticism regarding its marketing practices, safety profile, and off-label usage. In 2009, manufacturer Eli Lilly pleaded guilty to illegally marketing the drug for unapproved uses and agreed to pay a $1.4 billion fine, one of the largest corporate settlements in history. Internal documents revealed the company downplayed serious health risks to protect sales, despite knowing the drug caused significant weight gain and elevated blood sugar. \r\n\r\nThe medication carries a Boxed Warning for an increased risk of death in elderly patients with dementia-related psychosis, leading to its prohibition for this condition. Critics argue it is frequently prescribed off-label for conditions like insomnia, anxiety, and ADHD in children and the elderly, despite a lack of strong evidence supporting its efficacy for these uses. \r\n\r\nCommon adverse effects drive much of the patient criticism, including rapid weight gain, hyperglycemia, and diabetes. Users frequently report severe side effects such as tardive dyskinesia, sedation, emotional numbness, and difficult withdrawal symptoms (discontinuation syndrome), with some claiming the drug permanently alters personality and brain chemistry. Additionally, studies have linked atypical antipsychotics like Zyprexa to a higher risk of cardiovascular events, including heart attacks and strokes.",
"sig": "c812661565cbb1245e32e1e62338cee8359c28bd54ed0d7909a0fe8f0dc125784085043dd2836c041ed5499eab7bd3d2b9766d14be341bf5437966c3f7708c8d"
}